Nano Holdings,Inc.

4571 TSE Pharmaceuticals Pharmaceutical
TSE Growth
¥100.00
+1.01%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Moderate debt: debt-to-equity of 0.66.
  • Current assets comfortably cover current liabilities (current ratio 5.28).

!Watch-points

  • Thin interest cover: operating profit covers interest only about -41.8 times.
  • Return on equity is on the lower side at -27.7%.
  • Return on capital employed is on the lower side at -19.6%.
  • The company reported a net loss in the latest period.
  • Sales growth has been slow over five years (about -10% a year).

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreDistress zone
-0.59

In Altman’s study, scores in this range were associated with a higher incidence of financial distress.

Computed without the market-value term.

Piotroski F-ScoreWeak
3 / 4

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 4 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap¥84億
Current Price¥ 100.00
High / Low¥ 254.00 / 93.00
Stock P/E-7.75
Book Value¥ 43.11
Dividend Yield0%
ROCE-19.62%
ROE-27.70%
Debt to Equity0.66
Current Ratio5.28
P/B Ratio2.5197167
EPS¥ -12.90
PAT Margin-540.91%
ICR-41.75
Compounded Sales Growth
10 Years
5 Years -9.84%
3 Years
TTM
Compounded Profit Growth
10 Years
5 Years
3 Years
TTM
Stock Price CAGR
10 Years
5 Years
3 Years
1 Year
Return on Equity
10 Years
5 Years
3 Years
Last Year -27.70%
Educational data only. Not a recommendation to buy, sell or hold any security.